DURHAM, N.C. - Scorpius Holdings, Inc. (NYSE American: SCPX), a contract development and manufacturing organization, revealed today its plan for an underwritten public offering of its common stock shares. The company, which specializes in large molecule biologic and cell therapy program development and manufacturing, will sell all the offered shares.
ThinkEquity is serving as the sole book-running manager for the public offering. Scorpius Holdings intends to allocate the net proceeds from this offering to bolster working capital and for general corporate purposes.
The offering is pursuant to a shelf registration statement on Form S-3, initially filed with the U.S. Securities and Exchange Commission (SEC) on December 10, 2020, and declared effective on December 22, 2020.
The sale of these securities will be conducted solely through a written prospectus. A preliminary prospectus supplement, along with the accompanying base prospectus, will be made available on the SEC's website and can also be obtained from ThinkEquity's New York office.
Scorpius Holdings emphasized that this press release is not an offer to sell or a solicitation of an offer to buy the securities, and there will be no sales in jurisdictions where such an offer, solicitation, or sale would be illegal prior to registration or qualification under the respective securities laws.
The company's state-of-the-art facilities in San Antonio, TX, offer a range of services, from analytical testing to process development and manufacturing. Scorpius Holdings prides itself on its transparent collaboration and high-quality biologics manufacturing capabilities.
The press release also contains forward-looking statements, which are based on current expectations and projections about future events. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated.
Investors are cautioned to read the preliminary prospectus supplement and accompanying base prospectus in their entirety, as well as other SEC filings by the company, for a more comprehensive understanding of Scorpius Holdings and the proposed offering. The company has stated it will not update any forward-looking statements in the press release unless required by law.
This article is based on a press release statement from Scorpius Holdings, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.